We have located links that may give you full text access.
Case Reports
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Systemic cyclosporine A in severe atopic keratoconjunctivitis.
Ophthalmology 1997 August
OBJECTIVE: Atopic keratoconjunctivitis (AKC) is a potentially blinding disease. It is usually associated with atopic dermatitis that has been managed successfully with systemic cyclosporine A (CSA) in some severe forms of the disease. In this study, the authors evaluated systemic CSA therapy in patients with severe AKC.
DESIGN: Cohort Retrospective study.
PARTICIPANTS: Four patients aged 31 to 64 with severe AKC and atopic dermatitis refractory to or dependent on steroid therapy.
INTERVENTION: The patients received oral CSA.
MAIN OUTCOME MEASURES: Ocular inflammation, skin condition, CSA treatment methods (dosage, duration), CSA-related side effects.
RESULTS: Daily dosage of oral CSA was 3 to 5 mg/kg and mean duration of treatment was 37 months (range, 22-48 months). Ocular inflammation was controlled totally in three patients. One patient responded only partially to treatment. Side effects included renal toxicity in one patient. Reduction of CSA dosage resulted in normalization of serum creatinine level.
CONCLUSIONS: This report suggests that systemic CSA represents an interesting alternative therapy in severe AKC.
DESIGN: Cohort Retrospective study.
PARTICIPANTS: Four patients aged 31 to 64 with severe AKC and atopic dermatitis refractory to or dependent on steroid therapy.
INTERVENTION: The patients received oral CSA.
MAIN OUTCOME MEASURES: Ocular inflammation, skin condition, CSA treatment methods (dosage, duration), CSA-related side effects.
RESULTS: Daily dosage of oral CSA was 3 to 5 mg/kg and mean duration of treatment was 37 months (range, 22-48 months). Ocular inflammation was controlled totally in three patients. One patient responded only partially to treatment. Side effects included renal toxicity in one patient. Reduction of CSA dosage resulted in normalization of serum creatinine level.
CONCLUSIONS: This report suggests that systemic CSA represents an interesting alternative therapy in severe AKC.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app